S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CYTH

Cyclo Therapeutics News Headlines

$1.98
-0.07 (-3.41%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.95
$2.10
50-Day Range
$1.98
$3.21
52-Week Range
$1.88
$13.00
Volume
26,605 shs
Average Volume
26,192 shs
Market Capitalization
$16.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.76
Get Cyclo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Cyclo Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYTH
News Sentiment

1.26

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYTH Articles
This Week

2

1

CYTH Articles
Average Week



Cyclo Therapeutics (NASDAQ:CYTH) News Headlines Today

SourceHeadline
finance.yahoo.com logoCyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 18 at 9:47 AM
finance.yahoo.com logoCyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
finance.yahoo.com - May 13 at 1:18 AM
finance.yahoo.com logoCyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
finance.yahoo.com - May 9 at 12:13 PM
finance.yahoo.com logoCyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
finance.yahoo.com - March 29 at 11:29 AM
finance.yahoo.com logoCyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
finance.yahoo.com - March 24 at 4:43 PM
finance.yahoo.com logoCyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
finance.yahoo.com - March 23 at 9:05 AM
benzinga.com logoCyclo Therapeutics Earnings Perspective: Return On Capital Employed
benzinga.com - March 15 at 3:07 PM
finance.yahoo.com logoCyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
finance.yahoo.com - March 14 at 8:54 AM
finance.yahoo.com logoCyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
finance.yahoo.com - March 10 at 8:29 AM
finance.yahoo.com logoCyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
finance.yahoo.com - February 8 at 12:52 PM
finance.yahoo.com logoCyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
finance.yahoo.com - February 3 at 8:43 AM
finance.yahoo.com logoCyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
finance.yahoo.com - January 20 at 10:00 AM
finance.yahoo.com logoJTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
finance.yahoo.com - January 12 at 11:10 AM
nasdaq.com logoCyclo Therapeutics Inc - Class A Shares Fall 3.9% Below Previous 52-Week Low - Market Mover
nasdaq.com - December 29 at 3:14 AM
finance.yahoo.com logoHere's Why Cyclo Therapeutics (NASDAQ:CYTH) Must Use Its Cash Wisely
finance.yahoo.com - December 16 at 8:59 AM
finance.yahoo.com logoCyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
finance.yahoo.com - December 9 at 9:13 AM
markets.businessinsider.com logoCyclo Gets FDA Approval For Phase 2 Study Of Trappsol Cyclo To Treat Early Alzheimer's Disease
markets.businessinsider.com - December 6 at 9:36 AM
finance.yahoo.com logoCyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
finance.yahoo.com - December 6 at 9:36 AM
baystreet.ca logoCyclo Falls After IPO
baystreet.ca - November 17 at 1:11 PM
finance.yahoo.com logoCyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
finance.yahoo.com - November 17 at 1:10 AM
finance.yahoo.com logoCyclo Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 16 at 8:10 PM
nasdaq.com logoCyclo Therapeutics Adds 5% After Submitting IND To Evaluate Trappsol Cyclo For Alzheimer's Disease
nasdaq.com - November 16 at 3:09 PM
finance.yahoo.com logoCyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
finance.yahoo.com - November 16 at 10:08 AM
finance.yahoo.com logoCyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 15 at 6:20 PM
finance.yahoo.com logoCyclo Therapeutics to Present at the Virtual Investor Roundtable Event
finance.yahoo.com - November 10 at 10:09 AM
finance.yahoo.com logoCyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
finance.yahoo.com - November 2 at 9:32 AM
finance.yahoo.com logoCyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
finance.yahoo.com - October 19 at 1:51 PM
finance.yahoo.com logoCyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
finance.yahoo.com - October 18 at 12:47 PM
finance.yahoo.com logoCyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
finance.yahoo.com - October 6 at 12:00 PM
finance.yahoo.com logoCyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
finance.yahoo.com - September 27 at 10:32 AM
finance.yahoo.com logoCyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
finance.yahoo.com - September 15 at 9:11 AM
finance.yahoo.com logoCyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 6:26 PM
finance.yahoo.com logoCyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 17 at 8:21 AM
finance.yahoo.com logoCyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder
finance.yahoo.com - July 30 at 10:32 PM
nasdaq.com logoCyclo Therapeutics Reports Positive Data From Phase 1 Study On Trappsol Cyclo For NPC Treatment
nasdaq.com - July 30 at 12:26 PM
finance.yahoo.com logoCyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
finance.yahoo.com - July 30 at 12:26 PM
businesswire.com logoCyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol ® Cyclo™
businesswire.com - July 27 at 2:44 PM
finance.yahoo.com logoCyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
finance.yahoo.com - July 27 at 9:44 AM
finance.yahoo.com logoCyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
finance.yahoo.com - June 21 at 9:31 AM
finance.yahoo.com logoHere's Why Some Shareholders May Not Be Too Generous With Cyclo Therapeutics, Inc.'s (NASDAQ:CYTH) CEO Compensation This Year
finance.yahoo.com - June 19 at 11:57 AM
finance.yahoo.com logoCyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
finance.yahoo.com - June 17 at 9:26 AM
finance.yahoo.com logoCyclo Therapeutics Announces Launch of New Website
finance.yahoo.com - June 15 at 9:41 AM
businesswire.com logoCyclo Therapeutics Announces Inclusion in the Russell 2000 ® Index
businesswire.com - June 14 at 11:32 PM
finance.yahoo.com logoCyclo Therapeutics Announces Inclusion in the Russell 2000® Index
finance.yahoo.com - June 14 at 8:31 AM
nasdaq.com logoWe're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
nasdaq.com - June 12 at 10:57 AM
finance.yahoo.com logoWill Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?
finance.yahoo.com - June 12 at 10:57 AM
finance.yahoo.com logoCyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 9 at 1:05 PM
finance.yahoo.com logoCyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 17 at 11:29 AM
finance.yahoo.com logoCyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
finance.yahoo.com - May 11 at 10:16 AM
finance.yahoo.com logoCyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
finance.yahoo.com - April 27 at 12:26 PM
Get Cyclo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.